Page 136 - MemoriaBBN-Eng

RESEARCH GROUPS

ç

PROGRAMME:
Drug Delivery and Targeting Group

Nanomedicine
(GDLF-HUVH)
á

ó
Group Members
íLead Researcher
íó
íSchwartz Navarro, Simó
STAFF MEMBERS
á
Foradada Felip, Laia
á
Gener, Petra ú
Contact:
Pla Solans, Helena

Hospital Valle Hebron. Barcelona. Santos Benito, Fernando Fidel
Passeig Vall d’hebron, 119-129.
ASSOCIATED MEMBERS
Phone: (+34) 93 489 40 53 é
E.mail: [email protected] · Website: http://www.cibbim.eu/
Abasolo Olaorta, Ibane
Alijotas Rein, Jaume

Arango Del Coro, Diego
Aristizabal Corrales, David Main lines of research

Armengol Carrasco, Manuel
Our group develops research projects mainly focused on oncology and rare
Espn Basany, Eloy
Fernndez Amurgo, Yolanda diseases.

Lpez Cano, Manuel
These projects are conducted around three preferred work areas:

CONTRIBUTORS
• Area 1: biomarkers and therapeutic targets from suitable experimental
Andretta, Elena models, as molecular biomarkers, diagnostic providers in biosensors (na-

Bazzocco, Sarah nodiagnosis) or for biofunctionalizing new nanomedicines and therapeutic

Ejarque Ortiz, Aroja targets for designing new more effective treatments or alternative thera-
Garca Aranda, Natalia peutic strategies (new nanomedicines).

Garca Latorre, Laura • Area 2: experimental chemistry and applied nanotechnology, especially
Gonalves Rodrigues, Paulo Andr
enhancing the study of polymeric nanomedicines, through simpler chemi-
Mougan Albela, Isabel
Pujol Esclusa, Anna cal synthesis designs and potential scalability, as well as new experimental
genomic therapies (iRNA, artificial non-viral vectors, etc.) and the study
Salas Torras, Anna
of biomedical applications based on nanotechnology (biosensors) and new
Srkny, Vince
Says Ortega, Joan
biomaterials.

• Area 3: Validation of targets and functional studies. This is essential for
obtaining concept tests and preclinical studies of new biomarkers and tar-

gets, as well as of new nanomedicines including: biodistribution, toxicity,

therapeutic activity, specificity, functional molecular studies, etc..., in diffe-
rent in vitro and in vivo experimental models.

TECHNOLOGICAL PLATFORM ON NANOMEDICINE.

The in vivo experimentation unit allows data to be obtained on the systemic 13
behaviour of biomarkers (biodistribution, pharmacokinetics, pharmacodyna- 20
T
mics, toxicity and therapeutic activity) using imaging techniques, combining R
invasive and non-invasive procedures.
PO
E
This unit also enables nanomedicine-based therapies to be tested on con- L R
A
ventional cell lines and primary cultures (loss and gain of function experi- NU
N
ments and gene expression analysis, as well as studying control of expres- A
sion at various levels: transcriptional [gene transfection, inducible systems], /
BN
posttranscriptional [RNAi] and at the protein level [antagonists and antibody B
neutralization]).
R-
BE
CI

136